Extended Investigation of Exposure to Respirable Synthetic Amorphous Silica Dust and Its Potential Impact on Non-malignant Respiratory Morbidity

Mei Yong*, Peter Morfeld² and Robert McCunney³

¹ MY EpiConsulting, Duesseldorf, Germany, ² Private Scientist, Schwerte, Germany, ³ Brigham and Women’s Hospital, Harvard Medical School Boston, Boston, MA, United States

Objectives: The present analysis aims to study the health impact of an occupational exposure to respirable synthetic amorphous silica (SAS) dusts, based on the available data from the German study.

Methods: The effect of cumulative exposure to respirable SAS dust on respiratory morbidity were investigated in 462 exposed male workers. Multiple exposure assessments was performed anchored by a most recent measurement series. Internal regression models in addition to Monte Carlo-Multi Model were fitted.

Results: An averaged cumulative respirable SAS dust concentration of 6.44 mg/m³-years was estimated. Internal regression models suggested a reduction of 8.11 ml (95% confidence interval: 0.49–15.73) in forced vital capacity (FVC) per 1 mg/m³-year increase of exposure. But no effect on forced expiratory volume in 1 s (FEV₁) and the ratio of the parameters FEV₁/FVC was observed in association with exposure to a respirable fraction of SAS. No adverse effects on the occurrence of respiratory diseases were indicated.

Conclusion: This study provides no clear evidence of adverse health effects from occupational exposure to respirable SAS.

Keywords: respirable synthetic amorphous silica, lung function, epidemiology, modeling, occupational exposure

INTRODUCTION

Pyrogenic and precipitated synthetic amorphous silica (SAS) are nanostructured polymorphs of silicon dioxide, according to the International Organization for Standardization (ISO) definition that “material with any external dimension in the nanoscale or having an internal structure or surface structure in the nanoscale.” Nanoscale is defined as a size range from ~1 to 100 nm.
Workers can be exposed to dusts of SAS during production and use of the material. Pyrogenic and precipitated SAS have the internal structure of primary particles in the nanoscale. However, the aggregate is the smallest divisible entity for an amorphous material like SAS.

Note, Synthetic amorphous silica must be distinguished from crystalline silica. Whereas, adverse health effects from exposure to crystalline silica dust have been identified and studied for decades [e.g., (1)] the situation for chronic SAS dust exposure among humans is quite different. The International Agency for Research on Cancer (IARC) classified crystalline silica as a human lung carcinogen but amorphous silica was categorized into group 3, i.e., “not classifiable as to its carcinogenicity to humans” (2). No cancer risk was linked to SAS dust exposure. Therefore, the major interest in exposure to SAS is the potential for non-malignant respiratory effects. However, the documentation and assessment of published results on respiratory diseases in SAS exposed workers have been insufficient for drawing robust conclusions (3). This situation may be due to the fact that the amorphous forms have never drawn attention given their low toxicity potential (no known specific toxicity, amorphous structure, and solubility of SAS). However, according to a review, risk of respiratory diseases like chronic bronchitis from SAS exposure could not be ruled out (4).

Very few epidemiologic studies that investigated the exposure to amorphous silica and health outcomes are existing. Therefore, the documentation and assessment of published results on respiratory diseases in SAS exposed workers have been insufficient for drawing robust conclusions (3).

A cross-sectional study involving five German SAS production sites has been conducted to investigate the long-term exposure to inhalable SAS dust (5) and the effect on lung function parameters, such as forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and maximal expiratory flow at 50% of vital flow capacity (MEF50), respiratory diseases, such as chronic bronchitis, and chronic obstructive pulmonary disease (COPD) and pneumoconiosis (abnormalities in chest radiographs) in 484 exposed male workers from five German SAS production plants (6). Average effects of 80 mg/m³-years of cumulative inhalable SAS exposure on lung function were estimated (FVC: −48 ml, p = 0.04; FEV1: −28 ml, p = 0.16; MEF50/FVC: +0.2%, p = 0.39; MEF50: −12 ml, p = 0.76). The reduction of FVC was, however, unexceptional when compared to reference values from the non-smoking healthy general population. Hence, no concern for safety and health was substantiated under the existing working condition.

The size of particulate matter has been considered an important determinant of adverse health effects. A thorough review (7) provided a new perspective that the biological activity of SAS can be related to the particle shape and surface characteristics interfacing with the biological milieu rather than to particle size. In epidemiology, the potential health impact from the occupational exposure to SAS, in particular the respirable fraction, is less investigated.

The present study aims to address the potential impact of the respirable fraction of SAS on non-malignant respiratory morbidity with respect to lung function parameters, and prevalence of respiratory pattern, chronic bronchitis, and chronic obstructive pulmonary disease (COPD), we used the available data from the German study involving 462 SAS production workers (5, 6).

### MATERIALS AND METHODS

#### Study Population

The enumerated study population consists of 522 workers exposed to SAS working at five German plants producing either pyrogenic or precipitated SAS (5). The start exposure period of the five German plants varies from 1959 to 1978. Eligible to participate were all current full-time workers in 1997, who worked for at least 1 month at one of the plants. Due to the small number of female workers (about 5%), only male workers were included in the present analysis. Furthermore, 21 workers without exposure information, missing lung function data, missing prick test, and inconsistent data were excluded (6). In total, 462 exposed male workers were eligible for the present analysis. Among the 462 included workers, there are 158 (34%) workers at Plant 1, 29 (6%) at Plant 2, 165 (36%) at Plant 3, 39 (8%) at Plant 4, and 71 (15%) at Plant 5. All study participants gave their informed consent.

#### Exposure Assessment

Job-exposure matrices (JEMs) were applied to assess the individual cumulative exposure. Respirable SAS dust concentrations were measured at each of the plants. Within each plant, the same measurement devices were applied, while different teams took the measurement across the plants. The team for Plant 1, 3, and 4 (first team) acted as a trainer for the study teams at Plants 2 and 5. Person-related dust measurements were taken repeatedly and were individually documented. Each participant was measured twice at the first instance and depending on these two measurements a third, fourth, or even fifth measurement was performed. Workers with the same jobs were additionally measured and these measurements were used in later evaluations, although these additional workers were not treated as participants in this study. All measurements were taken in the period from 1997 to 2000 (5). Industrial hygiene and plant experts assessed all jobs across the five plants to create similar exposure groups (SEGs), which means that jobs were rated as one category if the exposure levels in the work environment were comparable (8). The seven different SEGs were categorized as 9 if the categorization was not possible and 0 for the lowest exposure category up to 5 for the highest exposure category. At each plant, changes in production, ventilation, housekeeping, and other factors were reported in detail for each year and SEG since the start of the SAS production. With this information, the experts could assess the exposure levels at each plant by relative scoring (9).

Together with the individual measurement data from the period 1997 to 2000 these relative estimates were anchored to derive the respirable SAS dust concentration estimates for the complete exposure period (10). To do so, a multiple SAS exposure assessment was performed with five calculated statistics to function as anchor values for the individual measurement data.
These five statistics were p25 (first quartile), median, p75 (third quartile), the geometric, and the arithmetic mean. Furthermore, uncertainties in relative scoring were assessed by the experts by estimating low, medium, and high relative SAS dust level changes. Routine data from personnel files of the five plants were used to create the individual working history of each worker. With the anchoring method (p25, median, p75, geometric and arithmetic mean) and the type of backward extrapolation (low, medium, high), an array of 15 exposure scenarios were presented as follows, which led to 15 JEMs.

- kum1: median_high scenario
- kum2: mean_medium scenario
- kum3: mean_low scenario
- kum4: p75_high scenario
- kum5: p75_medium scenario
- kum6: p75_low scenario
- kum7: median_high scenario
- kum8: median_medium scenario
- kum9: median_low scenario
- kum10: p25_high scenario
- kum11: p25_medium scenario
- kum12: p25_low scenario
- kum13: geometric_high scenario
- kum14: geometric_medium scenario
- kum15: geometric_low scenario

This data was then combined with the job histories to constitute an individual exposure profile and across time to derive 15 basic estimates of cumulative exposure to respirable SAS dust for every worker in the study (11, 12). The procedure is described in detail in earlier publications (5, 6).

In analogy to the exposure assessment of inhalable SAS dust (5), the kum8 scenario (median-medium) was based on the medium backward extrapolation estimate anchored at the median of the respirable SAS dust measurements and was less affected by outliers. The kum8 scenario yielded the estimates which proved to present the best agreement with the estimates derived from another JEM procedure based on expert judgments. Therefore, it was chosen to serve as the leading exposure scenario when exploring potential health effects due to respirable SAS dust exposure.

**Definition of Health Outcomes**

Information regarding demographics, height, occupational history (including prior exposures and co-exposures to hazardous substances), smoking habits, medical history, and current respiratory symptoms were collected with the baseline questionnaires. Interviewers differed between plants and the questionnaires were either interviewer- or self-administered. The prevalence of respiratory diseases, including chronic bronchitis, chronic obstructive pulmonary disease (COPD), and pneumoconiosis was then determined based on the questionnaires. For chronic bronchitis, the WHO definition of cough and sputum for at least 3 months in at least two consecutive years was applied (13–15). The diagnosis of COPD was based on the GOLD criteria (16, 17). For analysis, two categories, COPD ≥ I and COPD ≥ II, were defined based on lung function data only. Additionally, obstructive chronic bronchitis was defined as COPD ≥ I and COPD ≥ II based on lung function data and the presence of chronic bronchitis. Using poster anterior chest radiographs according to the International Labor Office (ILO) classification 1980, pneumoconiosis was defined as profusion category ≥ I/0 (any type: 1/0 or 1/1) by at least one of the three independent readers (18). Atopy was assessed by a skin prick test using four different allergens (cat, grass, birch, and house dust mite). Furthermore, IgE antibodies for several environmental allergens were applied for atopy assessment.

Spirometry was performed by occupational physicians working at the different plants or a technician of the Institute of Preventive and Occupational Medicine (IPA) (at Plant 2). All measurements were either taken with Masterlab® (Plant 3 and Plant 4), portable pneumotachographs (Flowscreen®, Plant 1 and Plant 5), or Masterscope® (Plant 2) to obtain the forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, and maximal expiratory flow at 50% of vital flow capacity (MEF50). Each of the devices was produced by the former German company Viasys and used the same pneumotachograph. The measurements were performed according to the recommendations of the American Thoracic Society (19), but FEV1 and MEF50 were based on the best FVC maneuver. For each of the three lung function parameters FEV1, MEF50, and FVC at least three satisfying forced expiratory maneuvers were done. For Plant 3 and 4, only the best maneuver for FEV1, MEF50, and FVC was used.

Afterward, values for FVC, FEV1, FEV1/FVC ratio, and MEF50 of each worker were expressed as Z-scores according to the reference values according to Quanjer et al. (20) (European Respiratory Society). These Z-scores were then compared to the −1.64 for the lower limit of normality (LLN), i.e., the lower 5% of a normal distribution, to define the respiratory patterns, such as normal (FEV1/FVC ≥ LLN and FVC ≥ LLN), obstructive (FEV1/FVC < LLN), or restrictive pattern (FEV1/FVC ≥ LLN but FVC < LLN) (21).

**Statistical Analyses**

The continuous variables of the baseline study characteristics and the spirometry parameters were described with mean ± standard deviation (SD), median and interquartile range (IQR), while the categorical variables were summarized in counts and percentages. Multivariable linear regression models were performed to estimate the effect of a unit increase of cumulative respirable SAS dust exposure (1 mg/m³-year) on the lung function parameters (FEV1 in ml, FVC in ml, FEV1/FVC-ratio in %, MEF50 in ml) by the median-medium scenario (kum8). The regression models included a set of covariates to adjust for potential confounding effects. The same covariates were used in the assessment of inhalable SAS dust exposure (6) were included in the models of the present study, to ease comparison between the effect estimates of inhalable and respirable SAS dusts. These covariates were planted effect (Plant 2–5 vs. Plant 1 as reference), age in years, height in cm, body mass index in kg/m², former and current smoker vs. non-smoker, pack-years of smoking corresponding 20 cigarettes per day during 1 year, atopy assessed by skin prick test and IgE antibodies, use of...
### TABLE 1 | Study characteristics for 462 SAS-exposed male workers.

| Characteristic                      | Mean (SD) | Median (IQR) | N (%)   |
|-------------------------------------|-----------|--------------|---------|
| Age (baseline) (yrs)                | 41.0 (9.8) | 39.5 (33.6–48.3) |         |
| Height (cm)                         | 176.6 (6.9) | 176.0 (172.0–181.0) |         |
| Body mass index (kg/m²)             | 27.2 (4.1)  | 26.8 (24.4–29.4)  |         |
| Duration of exposure (yrs)          | 13.2 (8.7)  | 11.6 (7.2–17.4)   |         |
| Year of hire                        | 1983 (9.2)  | 1985 (1977–1989)  |         |
| Year of termination                 | 1998 (1.4)  | 1998 (1996–1998)  |         |
| Smoking                             |           |               |         |
| Non-smoker                          | 109 (23.6) |               |         |
| Former smoker                       | 80 (17.3)  |               |         |
| Smoker                              | 273 (59.1) |               |         |
| Pack-Years of smoking               | 14.8 (15.2) | 12.0 (1.5–20.0) |         |
| WHO chronic bronchitis              |           |               |         |
| Yes                                 | 52 (11.3)  |               |         |
| No                                  | 410 (88.2) |               |         |
| GOLD obstructive chronic bronchitis (stage) | | | |
| 0                                   | 445 (96.3) |               |         |
| I                                   | 6 (1.3)    |               |         |
| II                                  | 11 (2.4)   |               |         |
| GOLD spirometric staging for COPD   |           |               |         |
| 0                                   | 393 (85.1) |               |         |
| I                                   | 45 (9.7)   |               |         |
| II+                                 | 24 (5.2)   |               |         |
| Atopy assessment by prick test      |           |               |         |
| Positive                            | 163 (35.3) |               |         |
| Negative                            | 299 (64.7) |               |         |
| Atopy assessment by spec. IgE       |           |               |         |
| Positive                            | 148 (32.0) |               |         |
| Negative                            | 314 (68.0) |               |         |
| Anti-obstructive medication         |           |               |         |
| Yes                                 | 14 (3.0)   |               |         |
| No                                  | 448 (97.0) |               |         |
| Prior exposure to fibrogenic dust   |           |               |         |
| Yes                                 | 77 (16.7)  |               |         |
| No                                  | 385 (86.3) |               |         |
| Prior exposure to substances causing obstruction | | | |
| Yes                                 | 126 (27.3) |               |         |
| No                                  | 336 (72.7) |               |         |
| Spirometry                          |           |               |         |
| FEV₁ (L)                            | 3.9 (0.8)  | 3.8 (3.4–4.4)   |         |
| >LLN                                | 410 (88.7) |               |         |
| ≤LLN                                | 52 (11.3)  |               |         |
| FVC (L)                             | 5.1 (0.9)  | 5.0 (4.5–5.7)   |         |
| >LLN                                | 436 (94.4) |               |         |
| ≤LLN                                | 26 (5.6)   |               |         |
| FEV₁/FVC                            | 0.8 (0.1)  | 0.8 (0.7–0.8)   |         |
| >LLN                                | 394 (85.3) |               |         |
| ≤LLN                                | 68 (14.7)  |               |         |
| Respiratory outcome                 |           |               |         |
| Normal                              | 367 (79.4) |               |         |
| Obstructive pattern                 | 79 (17.1)  |               |         |
| Restrictive pattern                 | 16 (3.5)   |               |         |

(Continued)

### TABLE 1 | Continued

| Characteristic                      | Mean (SD) | Median (IQR) | N (%)   |
|-------------------------------------|-----------|--------------|---------|
| Small opacities (radiograph)        |           |               |         |
| Rounded                             |           |               |         |
| 0/0                                 | 415 (89.8) |               |         |
| 0/1                                 | 23 (5.0)   |               |         |
| N/A                                 | 24 (5.2)   |               |         |
| Irregular                           |           |               |         |
| 0/0                                 | 379 (86.5) |               |         |
| 0/1                                 | 50 (11.4)  |               |         |
| N/A                                 | 24 (5.2)   |               |         |
| Mixed                               |           |               |         |
| 0/0                                 | 435 (94.2) |               |         |
| 0/1                                 | 3 (0.7)    |               |         |
| N/A                                 | 24 (5.2)   |               |         |

LLN: −1.64 according to GLI 2012.
N/A, chest radiograph not available; SD, standard deviation.

![FIGURE 1](image-url) Average respirable SAS dust concentrations (median-medium scenario) and cubic spline function by calendar time with 0.95-confidence limits, 462 SAS exposed male workers.
increase of 1 mg/m$^3$-year. Next to the regression models on the respiratory impairment, multivariable logistic regression models on respiratory diseases (chronic bronchitis, obstructive chronic bronchitis, and COPD) and cumulative respirable SAS dust exposure have been conducted. Cumulative SAS exposure was categorized as ≤2, >2–≤6, and above 6 mg/m$^3$-year. These categories were based on the distribution, i.e. tertiles (2 mg/m$^3$ for 33.33% and 6 mg/m$^3$ for 66.66%) for the median-medium scenario. For smoking status, the categories of the current smoker and former smoker vs. non-smoker as in the linear regression models were used. Values of the lung function parameters measured in this study were expressed as a percentage of the Quanjer reference values and skewness and kurtosis have been calculated by the d’Agostino test for each distribution (20). Average respirable SAS dust concentrations (median-medium scenario) for the whole exposure period from 1960 to 2000 were estimated by spline regression and plotted as cubic spline with corresponding 95% confidence intervals for each exposure year. To investigate a potential dose-response relationship between respiratory impairment, respiratory diseases, and cumulative respiratory SAS dust exposure, restricted cubic splines using previous logistic regression models with the 5th, 50th, and 95th percentile as cubic knots have been calculated and plotted. Correlation between the inhalable and respirable SAS dust fraction of the 462 exposed male workers was calculated to determine the strength of the relationship between the two SAS types. Furthermore, this correlation was evaluated separately in each plant to check for plant-specific differences. Due to uncertainties in the anchoring and backward extrapolation for the exposure assessment, Monte Carlo simulations for the linear and logistic regression models as applied above have been performed with 10,000 repetitions for each of the regression models. The Monte Carlo procedure is described in detail previously (6). Fractional polynomials of degree two were used in order to take into account the possible non-linearity in age trends for the association of cumulative respirable SAS dust exposure and the lung function parameters. Additional age effects on the lung function parameters were assessed by calculating the age coefficients of lung function regression analyses according to reference values of the European Respiratory Society (20). These coefficients were compared to the age coefficients in this study for the whole study group of 462 exposed male workers and a subgroup aged 25 years and above.

All analyses were done with Stata 13 (23). Fractional polynomials were fitted with the “fracpoly” command. Monte Carlo regression analyses were performed with the “simulate” command. The statistical significance level was defined at 5%. Adjustment for multiple testing is not considered.

RESULTS

Characteristics of the Study Population

Characteristics of the study population are summarized in Table 1. The mean age at baseline was 41 years, the mean duration of exposure was 13.2 years and 59.1% of this study group were active smokers. A total of 52 cases of chronic bronchitis and 69 cases of COPD were counted among the workers. A total of 17 of the 52 cases with chronic bronchitis were additionally classified as obstructive chronic bronchitis. Cases with chronic bronchitis were identified by questionnaire and COPD cases by spirometry criteria only. Furthermore, there were 79 workers with an obstructive respiratory pattern, 16 workers with a restrictive respiratory pattern, and 367 workers with a normal respiratory pattern.

Exposure Assessment of Respirable SAS Dust

The correlation coefficients between the cumulative respirable SAS and inhalable SAS for the median-medium exposure scenario were examined, respectively, on a linear and logarithmic scale.

Strong correlation, ranging from 0.97 to 0.99 for all plants except for plant 2 (0.28) is indicated, with an overall correlation coefficient of 0.87 ($p < 0.001$). To control for the impact of the outlier measurements, the correlations were examined on the logarithmic scale as well. The correlation coefficients are generally improved, for plant 2 (0.60) particularly. An overall correlation coefficient of 0.92 ($p < 0.001$) was yielded.

Average respirable SAS dust concentrations (median-medium scenario) by calendar time with 0.95-confidence limits for all plants and workers are shown in Figure 1. Based on the median-medium scenario the mean SAS concentrations in mg/m$^3$ were extrapolated from 1956 (the first working year in the study population) onwards. Calendar time points with a respirable SAS dust concentration below 0 mg/m$^3$ were excluded. Until 1966, the mean SAS dust concentration reached its peak value of above 2.5 mg/m$^3$ before continuously decreasing to below 0.1 mg/m$^3$ in 2001. Even in the job category “bagging” with the highest levels of exposure the median dust concentration was below 0.6 mg/m$^3$ at each of the five plants.

Table 2 summarizes the statistics of the cumulative respirable SAS dust concentrations in mg/m$^3$-year for the 15 exposure scenarios of all 462 SAS-exposed male workers. Cumulative SAS dust concentrations varied considerably between the 15 exposure scenarios with a mean of 3.45 mg/m$^3$-year up to 21.97 mg/m$^3$-year. The exposure scenario used in the regression models in this study (median-medium scenario) had an average respirable SAS dust concentration of 6.44 mg/m$^3$-year and ranged from 0.2 to 62.7 mg/m$^3$-year.

Association Between Cumulative Respirable SAS Dust Exposure and Lung Function Parameters

Valid lung function measurements according to the quality criteria of the American Thoracic Society (19) were collected for FVC, FEV$_1$, and FEV$_1$/FVC in 462 SAS dust exposed male workers and in 456 SAS dust exposed male workers for MEF50.

External Comparisons

Figure 2 displays the results of external comparisons, based on the predictive values of the respective lung function parameters (FVC, FEV$_1$, FEV$_1$/FVC, MEF50) in relation to the reference values of the European Respiratory Society. Given statistics are mean, median, minimum, maximum, and the percentiles
### TABLE 2: Distribution of cumulative respirable SAS dust exposures in mg/m$^3$-year among the 15 exposure scenarios for 462 SAS-exposed male workers.

| Scenario (N = 462) | Min      | P5       | P25       | Mean       | SD        | P50       | P75       | P95       | Max       |
|-------------------|----------|----------|-----------|------------|-----------|-----------|-----------|-----------|-----------|
| 1 Mean-High       | 0.1242767| 0.8621879| 2.112276  | 18.38822   | 45.02148  | 5.086327  | 13.5319   | 71.5805   | 333.1182  |
| 2 Mean-Medium     | 0.1242767| 0.8621879| 2.099591  | 10.63807   | 16.15442  | 4.731598  | 11.81749  | 38.02087  | 105.2348  |
| 3 Mean-Low        | 0.0961178| 0.8621879| 2.099591  | 8.291332   | 9.819764  | 4.453384  | 10.38533  | 31.91607  | 68.39028  |
| 4 P75-High        | 0.1547988| 1.0875   | 2.795124  | 21.96905   | 59.1461   | 5.754957  | 14.34165  | 89.48982  | 439.2065  |
| 5 P75-Medium      | 0.1547988| 1.0875   | 2.718446  | 10.63807   | 20.06919  | 5.591762  | 11.5534   | 39.8041   | 138.5428  |
| 6 P75-Low         | 0.1093381| 1.0875   | 2.713178  | 8.938291   | 17.5261   | 5.536644  | 10.23994  | 29.48778  | 83.22604  |
| 7 Median-High     | 0.1497006| 0.536193 | 1.373239  | 10.45706   | 21.562    | 3.573217  | 9.571267  | 38.04878  | 152.3228  |
| 8 Median-Medium   | 0.1497006| 0.536193 | 1.340482  | 6.436606   | 8.339037  | 3.470625  | 7.77128   | 23.10788  | 62.6677   |
| 9 Median-Low      | 0.0948276| 0.536193 | 1.340482  | 5.133449   | 5.497449  | 3.312052  | 6.944469  | 16.27296  | 55.30203  |
| 10 P75-High       | 0.0923077| 0.3477631| 0.817757  | 7.280382   | 16.41187  | 2.354699  | 6.293403  | 30.15792  | 116.9589  |
| 11 P75-Medium     | 0.0923077| 0.3477631| 0.798005  | 4.35689    | 6.141231  | 2.246712  | 4.830932  | 16.65632  | 39.48246  |
| 12 P75-Low        | 0.0923077| 0.3333333| 0.798005  | 3.450836   | 3.95903   | 2.044882  | 4.086177  | 12.34656  | 34.85706  |
| 13 Geomean-High   | 0.1205337| 0.6104928| 1.54758   | 12.24693   | 28.64355  | 3.756728  | 9.841978  | 45.68624  | 209.8146  |
| 14 Geomean-Medium | 0.1205337| 0.6104928| 1.526232  | 7.14607    | 10.21232  | 3.672569  | 8.125386  | 23.24833  | 66.39297  |
| 15 Geomean-Low    | 0.0931322| 0.5966666| 1.479748  | 5.568611   | 6.087117  | 3.501494  | 6.899977  | 18.37606  | 49.44646  |

N, number of subjects; min, minimum; p5, 5th percentile; p25, 25th percentile; mean, arithmetic mean; sd, standard deviation; p50, median; p75, 75th percentile; p95, 95th percentile; max, maximum.

The exposure estimates based on median-medium scenario (in bold) are used for the regression analyses.

### FIGURE 2: Predictive lung function parameters (i) FVC, (ii) FEV1, (iii) FEV1/FVC, (iv) MEF50, relative to Quanjer reference value among 456 SAS exposed male workers.
TABLE 3 | Multivariable linear regression of FVC and cumulative respirable SAS dust exposure among 462 SAS-exposed male workers by median-medium scenario.

| Response FVC (ml) | Linear regression |
|-------------------|-------------------|
|                   | Estimate | SE | Robust 95% CI | P-value |
| Intercept         | -4,812.16 | 1,013.29 | -6,803.59 | -2,820.74 | 0.000 |
| Cumulative exposure (1 mg/m³-year) | -8.11 | 3.88 | -15.73 | -0.49 | 0.037 |
| Plant 2 vs. Plant 1 | -96.28 | 198.76 | -486.91 | 294.35 | 0.628 |
| Plant 3 vs. Plant 1 | -308.25 | 71.69 | -449.15 | -167.36 | 0.000 |
| Plant 4 vs. Plant 1 | -294.69 | 113.57 | -517.90 | -71.48 | 0.010 |
| Plant 5 vs. Plant 1 | 179.52 | 81.81 | 18.73 | 340.31 | 0.029 |
| Age (years)        | -28.10 | 3.91 | -35.79 | -20.42 | 0.000 |
| Height (cm)        | 64.77 | 5.18 | 54.59 | 74.95 | 0.000 |
| Body mass index (kg/m²) | -8.81 | 6.84 | -22.26 | 4.64 | 0.199 |
| Former smoker vs. non-smoker | 214.42 | 97.30 | 23.20 | 405.64 | 0.028 |
| Current smoker vs. non-smoker | -8.29 | 92.01 | -189.12 | 172.53 | 0.928 |
| Pack-Years of smoking | -2.96 | 2.87 | -8.61 | 2.68 | 0.302 |
| Atopy assessed by prick test (yes/no) | -24.35 | 73.40 | -168.61 | 119.91 | 0.740 |
| Atopy assessed by spec. IgE (yes/no) | 56.33 | 72.18 | -85.53 | 198.20 | 0.436 |
| Antibiotic medication (yes/no) | -242.18 | 253.75 | -740.88 | 256.53 | 0.340 |
| Prior exposure to fibrogenic dust (yes/no) | -92.10 | 85.66 | -260.44 | 76.25 | 0.283 |
| Prior exposure to substances causing obstruction (yes/no) | 75.98 | 72.65 | -66.79 | 218.75 | 0.296 |

95% CI, 95% confidence interval.

*P² = 0.496.

of interest. Additionally, standard deviation (s), skewness (sk), kurtosis (ku), and the p-values (p_sk, p_ku) of the d’Agostino test are reported. Furthermore, the fraction of observations below 80% of reference for FVC, FEV₁, and MEF50 and the fraction of ratios below 70% (16) for the FEV₁/FVC ratio are shown.

The predictive value of FVC yielded a mean value of ~106% and a median value of about 107%. Only 2.8% of the study population were found with FVC below 80% of the reference value. In parallel, the predictive value of FEV₁ yielded a mean value of about 99% and a median value ~100%. About 8.4% of the study subjects were found with FEV₁ below 80% of reference values. On average, a reduction of about 23% in comparison to the reference value was found, 14.5% of all measurements were below 70% of reference. The predictive value of MEF50 yielded a mean value of 79.5% and a median value of 77.3%, which made about 55.7% of all study subjects with MEF50 below 80% of the reference value.

Internal Comparisons

For internal comparisons, regression models provide the risk estimate per unit increase of cumulative exposure to respirable SAS, after adjustment for potential confounding factors. The effect estimates with respect to FVC are presented in Table 3. Cumulative exposure to respirable SAS dust (1 mg/m²-year) was negatively associated with FVC values with a reduction of 8.11 ml (p < 0.05). Apparent heterogeneity across the plants was observed. Compared to plant 1, Plant 3, and Plant 4 presented significantly reduced FVC values (p < 0.01). Another plant effect was found in Plant 5, which was positively associated with FVC values (p < 0.05).

Antibiotic medication showed a pronounced effect on FVC values in this model, though not reaching statistical significance in this model.

Including the same set of covariates, the risks of cumulative exposure to respirable SAS were estimated with respect to FEV₁, FEV₁/FVC, and MEF50 as well. The risk estimates from the multivariable linear regression of FEV₁, FVC, FEV₁/FVC, and MEF50 are summarized in Table 4.

With respect to FEV₁ (effect estimates in ml), the estimated coefficient of cumulative exposure to respirable SAS was not
TABLE 5 | Multivariable logistic regression of WHO chronic bronchitis and cumulative respirable SAS dust exposure among 462 SAS-exposed male workers by median-medium scenario.

| Characteristic                              | Obs = 462; median-medium scenario |
|---------------------------------------------|-----------------------------------|
|                                            | OR      | SE       | Robust 95% CI | P-value |
| Cumulative exposure (mg/m³-year)            |         |          |               |         |
| ≤2                                          | 1.00    |          |               |         |
| >2–≤6                                       | 2.02    | 0.83     | 0.90          | 4.54    | 0.090 |
| >6                                          | 1.03    | 0.55     | 0.36          | 2.93    | 0.957 |
| Plants                                      |         |          |               |         |
| 1                                           | 1.00    |          |               |         |
| 2                                           | 0.10    | 0.14     | 0.01          | 1.44    | 0.091 |
| 3                                           | 0.64    | 0.27     | 0.28          | 1.46    | 0.289 |
| 4                                           | 0.64    | 0.37     | 0.20          | 2.00    | 0.440 |
| 5                                           | 1.22    | 0.52     | 0.52          | 2.82    | 0.648 |
| Age (years)                                 | 1.03    | 0.03     | 0.98          | 1.07    | 0.299 |
| Height (cm)                                 | 0.97    | 0.01     | 0.95          | 0.99    | 0.000 |
| Body mass index (kg/m²)                     | 1.04    | 0.04     | 0.97          | 1.12    | 0.225 |
| Smoking                                     |         |          |               |         |
| Non-smoker                                  | 1.00    |          |               |         |
| Former smoker                               | 0.74    | 0.52     | 0.19          | 2.92    | 0.664 |
| Current smoker                              | 2.52    | 1.50     | 0.79          | 8.06    | 0.119 |
| Pack-Years of smoking                       | 1.03    | 0.01     | 1.00          | 1.05    | 0.064 |
| Atopy assessed by prick test                |         |          |               |         |
| No                                          | 1.00    |          |               |         |
| Yes                                         | 0.89    | 0.32     | 0.44          | 1.81    | 0.746 |
| Atopy assessed by spec. IgE                 |         |          |               |         |
| No                                          | 1.00    |          |               |         |
| Yes                                         | 0.80    | 0.30     | 0.38          | 1.68    | 0.548 |
| Antiobstructive medication                  |         |          |               |         |
| No                                          | 1.00    |          |               |         |
| Yes                                         | 7.40    | 4.68     | 2.14          | 25.56   | 0.002 |
| Prior exposure to fibrogenic dust           |         |          |               |         |
| No                                          | 1.00    |          |               |         |
| Yes                                         | 1.55    | 0.76     | 0.60          | 4.03    | 0.369 |
| Prior exposure to substances causing obstruction |         |          |               |         |
| No                                          | 1.00    |          |               |         |
| Yes                                         | 1.16    | 0.46     | 0.53          | 2.54    | 0.703 |

95% CI, 95% confidence interval; OR, odds ratio.

significant (p = 0.129). Significant effects were shown regarding the different plants, age, height, smoking, and anti-obstructive medication. Pronounced heterogeneity was observed across the plants. On average, FEV₁ values decreased by 30.55 ml per year of age (p < 0.01) and increased by 44.18 ml per cm increase of body height (p < 0.01). Smoking status (former smoker, current smoker vs. non-smoker) and pack years were included in the model at the meantime. Higher pack-years were associated with a decrease in FEV₁ values by 8.53 ml for each increment of pack-year (p < 0.01), while current smoking status was not significant. Former smokers showed a positive association with increased FEV₁ (p < 0.05). A very strong association was indicated from anti-obstructive medication, which was negatively associated with FEV₁ values (~468.5 ml, p < 0.05). BMI, atopy, or prior exposure did not show a statistically significant impact.

In contrast to the models of FVC, no significant effect on the FEV₁/FVC ratio was observed. Significant effects were found for plants, age, pack-year of smoking, anti-obstructive medication (p < 0.01), and height (p < 0.05).

With respect to MEF50, neither the cumulative exposure to respirable SAS dust nor the different plants yielded significant estimates, while age, more pack-years of smoking, and anti-obstructive medication were negatively associated with MEF50 (p < 0.01).
TABLE 6 | Multivariable logistic regression of chronic obstructive pulmonary disease (COPD) and cumulative respirable SAS dust exposure among 462 SAS-exposed male workers by median-medium scenario.

| Characteristic | Obs = 462; median-medium scenario |
|---------------|----------------------------------|
|               | OR | SE  | Robust 95% CI | P-value |
| **Cumulative exposure (mg/m³-year)** |     |     |             |         |
| ≤2            | 1.00 |     |             |         |
| >2–≤6         | 2.45 | 0.94 | 1.16 | 5.20 | 0.019 |
| >6            | 1.42 | 0.68 | 0.56 | 3.62 | 0.462 |
| **Plants**    |     |     |             |         |
| 1             | 1.00 |     |             |         |
| 2             | 0.06 | 0.59 | 0.01 | 0.40 | 0.003 |
| 3             | 0.61 | 0.23 | 0.29 | 1.28 | 0.189 |
| 4             | 1.06 | 0.57 | 0.37 | 3.03 | 0.907 |
| 5             | 0.89 | 0.38 | 0.38 | 2.07 | 0.792 |
| **Age (years)** |     |     |             |         |
| 1             | 1.02 | 0.02 | 0.98 | 1.06 | 0.422 |
| **Height (cm)** |     |     |             |         |
| 1             | 0.98 | 0.01 | 0.97 | 0.99 | 0.003 |
| **Body mass index (kg/m²)** |     |     |             |         |
| 1             | 1.00 | 0.04 | 0.93 | 1.08 | 0.980 |
| **Smoking**   |     |     |             |         |
| Non-smoker    | 1.00 |     |             |         |
| Former smoker | 0.99 | 0.51 | 0.36 | 2.72 | 0.982 |
| Current smoker| 0.75 | 0.44 | 0.24 | 2.35 | 0.625 |
| Pack-Years of smoking | 1.05 | 0.02 | 1.02 | 1.09 | 0.002 |
| **Atopy assessed by prick test** |     |     |             |         |
| No            | 1.00 |     |             |         |
| Yes           | 0.92 | 0.31 | 0.48 | 1.78 | 0.810 |
| **Atopy assessed by spec. IgE** |     |     |             |         |
| No            | 1.00 |     |             |         |
| Yes           | 0.87 | 0.31 | 0.43 | 1.74 | 0.689 |
| **Antiobstructive medication** |     |     |             |         |
| No            | 1.00 |     |             |         |
| Yes           | 4.04 | 2.48 | 1.21 | 13.43 | 0.023 |
| **Prior exposure to fibrogenic dust** |     |     |             |         |
| No            | 1.00 |     |             |         |
| Yes           | 0.91 | 0.46 | 0.34 | 2.45 | 0.852 |
| **Prior exposure to substances causing obstruction** |     |     |             |         |
| No            | 1.00 |     |             |         |
| Yes           | 0.85 | 0.31 | 0.42 | 1.72 | 0.654 |

95% CI, 95% confidence interval; OR, odds ratio.

**Association Between Cumulative Respirable SAS Dust Exposure and Respiratory Pattern, Chronic Bronchitis, and Chronic Obstructive Pulmonary Disease**

In Tables 5, 6, the results of the multinomial logistic regression of obstructive (FEV₁/FVC < LLN) and restrictive patterns (FEV₁/FVC > LLN and FVC < LLN) compared with normal spirometry (FEV₁/FVC > LLN and FVC ≥ LLN) according to the Global Lung Initiative (GLI) 2012 are shown (24). Cumulative exposure to respirable SAS dust (1 mg/m³-year) for the median-medium scenario did not reach significance for the obstructive pattern, but for the restrictive pattern (OR = 1.07; 95% CI = 1.01–1.12; p < 0.05). While for the restrictive pattern no significant odds ratio was found for the other covariates, pack years of smoking (OR = 1.03; 95% CI = 1.00–1.06; p < 0.05) and anti-obstructive medication (OR = 8.17; 95% CI = 2.12–31.53; p < 0.01) were significantly associated with the obstructive pattern.

The multivariable logistic regression of chronic bronchitis according to the WHO criteria and cumulative respirable SAS dust exposure based on the leading exposure estimate (median-medium scenario) among the 462 SAS-exposed male workers is shown in Table 5. Three categories were classified according to the cumulative exposure: ≤2 mg/m³-year as the reference category, >2–≤6, and >6 mg/m³-year. Neither the cumulative exposure categories (mg/m³-year) nor the different...
plants showed a significant effect on the development of chronic bronchitis. No exposure-response relationship was observed. 

Table 6 presents the multivariable logistic regression of COPD and cumulative respirable SAS dust exposure. Compared to the lowest exposure category (≤2 mg/m³-year), cumulative exposure to respirable SAS of 2–6 mg/m³-year seemed to increase the risk of developing COPD significantly (OR = 2.45; 95% CI = 1.16–5.20), while the highest exposure category (>6 mg/m³-year) was not associated with a significantly increased risk (OR = 1.42; 95% CI = 0.56–3.62). No exposure-response relationship could be concluded.

Table 7 summarizes the results of the Monte Carlo regression models on lung function parameters (FEV\(_1\), FVC, FEV\(_1\)/FVC, MEF50), and the prevalence of respiratory diseases (chronic bronchitis, COPD based on spirometric staging only). The risk estimates of cumulative respirable SAS dust exposure on the lung function parameters were not statistically significant for FEV\(_1\), FEV\(_1\)/FVC, and MEF50, while −8.11 (95% CI: −15.71–0.51) ml decline of FVC was implied. No increased risk of chronic bronchitis and COPD was indicated.

Table 8 shows the effect of age on lung function parameters according to the reference values of the European Respiratory Society published in the study by Quanjer et al. (20) and additionally the estimated effect in this study for the whole study population. For the whole study population, the risk of developing COPD significantly (OR = 1.16–5.20), while the highest exposure category (1 mg/m³-year) was not associated with a significantly increased risk (OR = 0.51).

**Discussion**

The present extended analyses aimed to investigate the effect of cumulative exposure to respirable SAS dust on non-malignant respiratory morbidity. The endpoints are (i) lung function parameters (FEV\(_1\), FVC, FEV\(_1\)/FVC-ratio, and MEF50); (ii) respiratory pattern (restrictive and obstructive pattern); (iii) respiratory diseases (chronic bronchitis and COPD in 462 exposed male workers of five German plants producing synthetic amorphous silica (SAS). Individual cumulative SAS exposure was calculated by backward extrapolation using 15 different JEMs adapted for uncertainties in historical exposure level estimates. These JEMs were based on anchoring individual working histories; information on changes in production, ventilation, housekeeping, and similar exposure groups (SEGs), and other factors in each plant with the actual SAS measurements in the period of 1997 to 2000.

To our knowledge, apart from the study of Taeger et al. (6) upon which the population of this study was based, only two human studies on occupational SAS exposure and pulmonary function have been performed (25, 26). The cross-sectional study by Wilson et al. consisted of 165 amorphous silica workers. Results showed that pulmonary function and radiographic changes were not significantly associated with.
neither duration nor total cumulative SAS exposure. In the study of Choudat et al. (25), 41 workers exposed to amorphous silica were compared with an age-matched control group of 90 non-exposed workers at the same plant. Significant differences between exposed and non-exposed workers were found for lung function parameters of forced expiratory forces. No exposure-response relationship was suggested. Both studies suffered from weak exposure assessments, no distinction between inhalable and respirable dust, and no proper adjustments for covariates. The third study reported the adverse health outcome of exposure to inhalable SAS dust (6). To overcome the uncertainties in exposure assessment, tremendous effort was given to check the robustness of exposure estimates, please refer to Morfeld et al. (5). A reduction in FVC, but no effect on FEV1 and FEV1/FVC was observed in association with exposure to an inhalable fraction of SAS.

The present study reported the evaluation of the health effects of exposure to a respirable fraction of SAS, based on the same study population of Taeger et al. (6). In analog, the leading median-medium scenario among 15 JEMs has been used to estimate cumulative SAS exposure for the present study. Results from the multivariable linear regression models did not indicate any adverse effect on FEV1 and FEV1/FVC, but a reduction in FVC as a result of exposure to respirable SAS (cf. Table 3).

An estimated loss in FVC of ~48 ml resulting from a cumulative exposure of 6.44 mg/m3-years needs a discussion. We compared this amount of loss with the loss expected due to aging and smoking. Table 7 shows the age-dependency of lung function parameters according to the reference equations published in Quanjer et al. (20) and it presents the age coefficients estimated in this study for the whole study group and restricted to workers older than 25 years. We used the Quanjer equations to calculate the expected loss in FVC over 40 years: 26 ml/year *40 years = 1,040 ml. Thus, the estimated relative additional loss in FVC due to an exposure to respirable over 40 years was 48/1,040, i.e., ~5% (had we used the modeling results, this fraction was slightly smaller). Smokers were found to show a decline in FEV1 of about 60 ml/year (27, 28), equivalent to an additional loss of about 33 ml/year which amounts to an overall additional loss of 1,200 ml over 40 years. Thus, the relative additional loss due to smoking (1,320/1,040) is larger than 100%. Note that a smoker's additional decline in FVC is similar to the smoker's additional decline in FEV1 (29). Thus, we conclude that the additional lung function loss in FVC due to SAS dust exposure as estimated from the MC regression models appears to be negligible when compared to the regular loss due to aging and in particular when compared to the effect of smoking on lung function.

The major weakness of this cross-sectional study is a potential underestimation of exposure and effects since diseased workers might terminate the exposure and not be included in this study population. This so-called “Healthy Worker Survivor Effect” noted as a weakness of Taeger et al. (6) is difficult for the researchers to trace back when the diseased workers have left and the causes for the termination (6). The extensive exposure assessment is the key strength of the present study, using multiple exposure scenarios approach with Job Exposure Matrices as in the present study yields a robust estimate of historical exposure levels. Especially, when assessing historical exposures in different plants and for different job categories, it is important to use an approach that deals with uncertainties in exposure measurements and exposure level changes in the past.

In general, the present cross-sectional study reports that historic workplace exposures to respirable SAS were not associated with respiratory morbidity. However, the effect of the respirable fraction seemed to be more relevant than that of the inhalable fraction, given the identical level of exposure. Since a cross-sectional study has its inherent limitation for causal inference because of the ambiguous temporal order of cause and outcome, a prospective follow-up study with extensive exposure assessment of nanoparticles would provide valid evidence for risk assessment.

DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because data protection directives.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the German Workers Council. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

PM, MY, and RM: study design, study conduction, and drafting and reviewing of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was funded by a research contract with Evonik Operations GmbH/Smart Materials, Cabot Corporation, and Wacker Chemie AG. The design, conduct, analysis, and conclusions of the study are exclusively those of the authors.

ACKNOWLEDGMENTS

We wish to thank the worker’s council, the occupational health service, the data protection officer and the experts of the involving production sites of Evonik Operations GmbH/Smart Materials, Cabot Corporation, and Wacker Chemie AG. Especially we thank the experts Mitura, Nordone, Bosch, Vormberg for their effort in exposure measurements, Drs. Bailer, Barthel, and Küpper for their outstanding engagement in health evaluation, and the former team members of Institute for Occupational Epidemiology and Risk Assessment (IERA) for data management and literature research.
REFERENCES

1. Greim H, Silica, Crystalline: Quartz Dust, Cristobalite Dust and Tridymite Dust (Respirable Fraction) The MAK Collection for Occupational Health and Safety. Vol. 12. Weinheim: Verlag Wiley-VCH (1999).

2. IARC. Silica, Some Silicates, Coal Dust and Para-Aramid Fibres. Vol. 68. Lyon: IARC.

3. ECETOC. IACCP Report No 51. Synthetic Amorphous Silica (CAS No. 7631-86-9). Brussels: ECETOC (2006).

4. Merget R, Bauer T, Küpper HU, Philippou S, Bauer H, Breitstadt R, et al. Health hazards due to the inhalation of amorphous silica. Arch Toxicol. (2002) 76:23–34. doi: 10.1007/s002040100266

5. Morfeld P, Taeger D, Mütura H, Bosch A, Nordone A, Vormberg R, et al. Cross-sectional study on respiratory morbidity in workers after exposure to synthetic amorphous silica at five german production plants: exposure assessment and exposure estimates. J Occup Environ Med. (2014) 56:72–8. doi: 10.1097/JOM.0000000000000555

6. Taeger D, McCunney R, Bailer U, Barthel K, Küpper U, Brüning T, et al. Cross-sectional study on nonmalignant respiratory morbidity due to exposure to synthetic amorphous silica. J Occup Environ Med. (2016) 58:376–84. doi: 10.1097/JOM.0000000000000666

7. Frujjier-Polloth C. The toxicological mode of action and the safety of synthetic amorphous silica—a nanostructured material. Toxicology. (2012) 294:61–79. doi: 10.1016/j.tox.2012.02.001

8. Ignacio JS, Bullock WH. A Strategy for Assessing and Managing Occupational Exposures. 3rd edition. Fairfax: AIHA Press (2006). doi: 10.3320/978-1-931504-69-0

9. Harber P, Muranko H, Shvartsblat S, Solis S, Torossian A, Oren T. A triangulation approach to historical exposure assessment for the carbon black industry. J Occup Environ Med. (2003) 45:131–43. doi: 10.1097/01.jom.0000052956.59271.bd

10. Dahmann D, Taeger D, Kappler M, Büchte S, Morfeld P, Bruning T, et al. Assessment of exposure in epidemiological studies: the example of silica dust. J Expo Sci Environ Epidemiol. (2008) 18:452–61. doi: 10.1038/sj. jes.7500636

11. Checkoway H, Pearce N, Kriebel D. Research Methods in Occupational and Environmental Health. New York: Oxford University Press (2004). doi: 10.1093/acprof:oso/9780195092424.001.0001

12. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd edition. Philadelphia, PA: Lippincott Williams & Wilkins (2008).

13. American Thoracic Society. Chronic bronchitis, asthma and pulmonary emphysema: a statement by the committee on diagnostic standards for nontuberculous respiratory diseases. Am Rev Respir Dis. (1962) 85:762–8.

14. Committee on Research into Chronic Bronchitis. Questionnaire in Respiratory Symptoms: Instructions for Its Use. London: Medical Research Council (1966).

15. WHO. Report of an Expert Committee: Definition and Diagnosis of Pulmonary Disease With Special Reference to Chronic Bronchitis and Emphysema. Geneva: WHO (1961).

16. GOLD. Spirometry for Health Care Providers. GOLD (2010). Available online at: http://www.goldcopd.org/pdf/GOLD%20SpirometryFull%5b1%5d.pdf (accessed October 10, 2018).

17. GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. GOLD (2011). Available online at: http://goldcopd.org/ (accessed October 10, 2018).

18. ILO. Richtlinien für die Anwendung der Internationalen Klassifikation des IAA von Pneumokoniosen-Röntgenfilmen. Geneva: ILO (1980).

19. ATS. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. (1995) 152:1107–36. doi: 10.1164/ajccm.152.3.7663792

20. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir Dis. (1993) 6(Suppl. 16):5–40. doi: 10.1183/09041950.050.1693

21. Vaz Fragoso CA, McAvay G, Gill TM, Concato J, Quanjer PH, Van Ness PH. Ethnic differences in respiratory impairment. Thorax. (2014) 69:55–62. doi: 10.1136/thoraxjnl-2013-203631

22. Cameron AC, Trivedi PK. Microeconomics. Methods and Applications. Cambridge: University Press (2005). doi: 10.1017/CBO9780511811241

23. StataCorp. Stata: Bootstrap—Reference Manual Release 13. StataCorp (2013). Available online at: http://www.stata.com/manuals13/bootstrap.pdf (accessed October 10, 2018).

24. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. (2012) 40:1324–43. doi: 10.1183/09031936.0080312

25. Choudat D, Frisch C, Barrat G, el Kholi A, Conso F. Occupational exposure to amorphous silica dust and pulmonary function. Br J Industr Med. (1990) 47:763–6. doi: 10.1136/oem.47.11.763

26. Wilson RK, Stevens PM, Lovejoy HB, Bell ZG, Richie RC. Effects of chronic amorphous silica exposure on sequential pulmonary function. J Occup Med. (1979) 21:399–402.

27. Anthonisen NR, Connell JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA. (1994) 272:1497–505. doi: 10.1001/jama.1994.03520190043033

28. Sircar K, Hnizdo E, Petsonk EL, Attfield M. Decline in lung function and mortality: implications for medical monitoring. Occup Environ Med. (2007) 64:641–6. doi: 10.1136/oem.2006.031419

29. Bossé R, Sparrow D, Rose CL, Weiss ST. Longitudinal effect of age and smoking cessation on pulmonary function. Am Rev Respir Dis. (1981) 123 (4 Pt. 1):378–81.

Conflict of Interest: MY was employed by MY EpiConsulting.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yong, Morfeld and McCunney. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.